198 related articles for article (PubMed ID: 30527810)
21. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
[TBL] [Abstract][Full Text] [Related]
22. Combined gene dosage requirement for SWI/SNF catalytic subunits during early mammalian development.
Smith-Roe SL; Bultman SJ
Mamm Genome; 2013 Feb; 24(1-2):21-9. PubMed ID: 23076393
[TBL] [Abstract][Full Text] [Related]
23. Functional redundancy of SWI/SNF catalytic subunits in maintaining vascular endothelial cells in the adult heart.
Willis MS; Homeister JW; Rosson GB; Annayev Y; Holley D; Holly SP; Madden VJ; Godfrey V; Parise LV; Bultman SJ
Circ Res; 2012 Aug; 111(5):e111-22. PubMed ID: 22740088
[TBL] [Abstract][Full Text] [Related]
24. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis.
Reisman DN; Sciarrotta J; Wang W; Funkhouser WK; Weissman BE
Cancer Res; 2003 Feb; 63(3):560-6. PubMed ID: 12566296
[TBL] [Abstract][Full Text] [Related]
25. BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency.
Gupta M; Concepcion CP; Fahey CG; Keshishian H; Bhutkar A; Brainson CF; Sanchez-Rivera FJ; Pessina P; Kim JY; Simoneau A; Paschini M; Beytagh MC; Stanclift CR; Schenone M; Mani DR; Li C; Oh A; Li F; Hu H; Karatza A; Bronson RT; Shaw AT; Hata AN; Wong KK; Zou L; Carr SA; Jacks T; Kim CF
Cancer Res; 2020 Sep; 80(18):3841-3854. PubMed ID: 32690724
[TBL] [Abstract][Full Text] [Related]
26. Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.
Reichl KD; Lee ECY; Gopalsamy A
Expert Opin Ther Pat; 2024 Mar; 34(3):159-169. PubMed ID: 38578210
[TBL] [Abstract][Full Text] [Related]
27. SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines.
Watanabe H; Mizutani T; Haraguchi T; Yamamichi N; Minoguchi S; Yamamichi-Nishina M; Mori N; Kameda T; Sugiyama T; Iba H
Oncogene; 2006 Jan; 25(3):470-9. PubMed ID: 16247481
[TBL] [Abstract][Full Text] [Related]
28. BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex-a tumour suppressor or tumour-promoting factor?
Jancewicz I; Siedlecki JA; Sarnowski TJ; Sarnowska E
Epigenetics Chromatin; 2019 Nov; 12(1):68. PubMed ID: 31722744
[TBL] [Abstract][Full Text] [Related]
29. SWI/SNF complexes are required for full activation of the DNA-damage response.
Smith-Roe SL; Nakamura J; Holley D; Chastain PD; Rosson GB; Simpson DA; Ridpath JR; Kaufman DG; Kaufmann WK; Bultman SJ
Oncotarget; 2015 Jan; 6(2):732-45. PubMed ID: 25544751
[TBL] [Abstract][Full Text] [Related]
30. SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature.
Nambirajan A; Singh V; Bhardwaj N; Mittal S; Kumar S; Jain D
Arch Pathol Lab Med; 2021 Jan; 145(1):90-98. PubMed ID: 33367658
[TBL] [Abstract][Full Text] [Related]
31. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression.
Reisman DN; Strobeck MW; Betz BL; Sciariotta J; Funkhouser W; Murchardt C; Yaniv M; Sherman LS; Knudsen ES; Weissman BE
Oncogene; 2002 Feb; 21(8):1196-207. PubMed ID: 11850839
[TBL] [Abstract][Full Text] [Related]
32. The BRG1 ATPase of human SWI/SNF chromatin remodeling enzymes as a driver of cancer.
Wu Q; Lian JB; Stein JL; Stein GS; Nickerson JA; Imbalzano AN
Epigenomics; 2017 Jun; 9(6):919-931. PubMed ID: 28521512
[TBL] [Abstract][Full Text] [Related]
33. Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features.
Matsubara D; Kishaba Y; Ishikawa S; Sakatani T; Oguni S; Tamura T; Hoshino H; Sugiyama Y; Endo S; Murakami Y; Aburatani H; Fukayama M; Niki T
Cancer Sci; 2013 Feb; 104(2):266-73. PubMed ID: 23163725
[TBL] [Abstract][Full Text] [Related]
34. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.
Xue Y; Meehan B; Fu Z; Wang XQD; Fiset PO; Rieker R; Levins C; Kong T; Zhu X; Morin G; Skerritt L; Herpel E; Venneti S; Martinez D; Judkins AR; Jung S; Camilleri-Broet S; Gonzalez AV; Guiot MC; Lockwood WW; Spicer JD; Agaimy A; Pastor WA; Dostie J; Rak J; Foulkes WD; Huang S
Nat Commun; 2019 Feb; 10(1):557. PubMed ID: 30718506
[TBL] [Abstract][Full Text] [Related]
35. High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer.
Guerrero-MartÃnez JA; Reyes JC
Sci Rep; 2018 Feb; 8(1):2043. PubMed ID: 29391527
[TBL] [Abstract][Full Text] [Related]
36. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
[TBL] [Abstract][Full Text] [Related]
37. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.
Lissanu Deribe Y; Sun Y; Terranova C; Khan F; Martinez-Ledesma J; Gay J; Gao G; Mullinax RA; Khor T; Feng N; Lin YH; Wu CC; Reyes C; Peng Q; Robinson F; Inoue A; Kochat V; Liu CG; Asara JM; Moran C; Muller F; Wang J; Fang B; Papadimitrakopoulou V; Wistuba II; Rai K; Marszalek J; Futreal PA
Nat Med; 2018 Jul; 24(7):1047-1057. PubMed ID: 29892061
[TBL] [Abstract][Full Text] [Related]
38. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
39. The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation.
Wu Q; Madany P; Akech J; Dobson JR; Douthwright S; Browne G; Colby JL; Winter GE; Bradner JE; Pratap J; Sluder G; Bhargava R; Chiosea SI; van Wijnen AJ; Stein JL; Stein GS; Lian JB; Nickerson JA; Imbalzano AN
J Cell Physiol; 2015 Nov; 230(11):2683-94. PubMed ID: 25808524
[TBL] [Abstract][Full Text] [Related]
40. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.
Romero OA; Torres-Diz M; Pros E; Savola S; Gomez A; Moran S; Saez C; Iwakawa R; Villanueva A; Montuenga LM; Kohno T; Yokota J; Sanchez-Cespedes M
Cancer Discov; 2014 Mar; 4(3):292-303. PubMed ID: 24362264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]